PHAR - Pharming Group N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

11.11

-0.68

(-5.76%)

At close: 03:19PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Short-term KST

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	11.79
Open	10.88
Bid	11.04 x 1200
Ask	13.52 x 800
Day's Range	10.88 - 11.80
52 Week Range	6.10 - 17.81
Volume	2,513
Avg. Volume	24,993

Market Cap	741.915M
Beta (5Y Monthly)	0.92
PE Ratio (TTM)	N/A
EPS (TTM)	-0.05
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-24% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PHAR

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

PR Newswire
Pharming announces sale of priority review voucher
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. ("Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.
PR Newswire
Pharming Group to attend the following Investor Conferences in June
Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following investor conferences in the month of June:
PR Newswire
Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders
Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.
PR Newswire
Pharming Group reports financial results for the first quarter of 2023
Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.
Simply Wall St.
Pharming Group's (AMS:PHARM) investors will be pleased with their decent 51% return over the last year
It hasn't been the best quarter for Pharming Group N.V. ( AMS:PHARM ) shareholders, since the share price has fallen...
PR Newswire
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023
Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.
Zacks
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
PR Newswire
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023
Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands.
PR Newswire
Notice of First Quarter 2023 Results
Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.
PR Newswire
Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023.
PR Newswire
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the first commercial shipments of Joenja® (leniolisib) to patients in the United States. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare and progressive primary immunodeficiency, in adult and pediatric patients 12 years of age and older.
PR Newswire
Pharming Group convenes the Annual General Meeting of Shareholders 2023
Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (Nasdaq: PHAR) announces that the Company's 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday, May 17, 2023, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company's website under Investors/Shareholder Meetings.
PR Newswire
Pharming Group announces the filing of its 2022 Annual Report and Form 20-F
Pharming Group N.V. ("Pharming" or "the Company") ( Euronext: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2022 (the "Period"). The Annual Report is available under the Financial Documents section of the Pharming website.
PR Newswire
Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days
Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.
Zacks
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
Benzinga
FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy
The FDA approved Pharming Group N.V.'s (NASDAQ: PHAR) Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the U.S. for APDS, a rare and progressive primary immunodeficiency. The FDA evaluated the Joenja application for APDS under Priority Review. Joenja is expected to launch in the US in early April and will be av
PR Newswire
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency. The FDA evaluated
Reuters
UPDATE 1-US FDA approves Pharming's immune disorder drug
The U.S. Food and Drug Administration (FDA) on Friday approved Dutch firm Pharming Group's drug to treat a rare genetic disorder that leads to a weakened immune system, the company said. Leniolisib, to be sold under the brand name Joenja, becomes the first approved drug to treat activated phosphoinositide 3-kinase delta syndrome (APDS), a primary immunodeficiency that affects about 1 to 2 people in a million. Joenja is expected to launch in the U.S. in early April and will be available for shipment in mid-April, Pharming said.
Simply Wall St.
Pharming Group Full Year 2022 Earnings: EPS: US$0.021 (vs US$0.025 in FY 2021)
Pharming Group ( AMS:PHARM ) Full Year 2022 Results Key Financial Results Revenue: US$205.6m (up 3.4% from FY 2021...
Zacks
Why Earnings Season Could Be Great for Pharming Group (PHAR)
Pharming Group (PHAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PR Newswire
Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcement
Pharming Group N.V. ("Pharming" or "the Company") ( Euronext Amsterdam: PHARM / Nasdaq: PHAR) is aware that Silicon Valley Bank Limited ("SVB UK") has today been sold to HSBC UK Bank plc. This transaction has been facilitated by the Bank of England, in consultation with the Treasury, using powers granted by the Banking Act 2009.
PR Newswire
Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcement
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) is aware that the US Department of the Treasury, the Board of Governors of the Federal Reserve System and the Federal Deposit Insurance Corporation ("FDIC") issued a joint statement on March 12, 2023 stating that actions have been approved enabling the FDIC to complete its resolution of Silicon Valley Bank ("SVB US") in a manner that fully protects all depositors. The statement further noted that deposit
Reuters
Dutch biotech Pharming says it held $45 mln in collapsed SVB
Dutch biotech firm Pharming said on Sunday it held $45 million in collapsed U.S. lender Silicon Valley Bank's British and U.S. units and that it will seek to recover the funds. Pharming said it held $26 million in SVB US and $19 million in SVB UK. "Pharming’s deposits with SVB US are largely uninsured and its deposits with SVB UK largely exceed the applicable protected limit."
PR Newswire
Pharming Group issues statement regarding the events surrounding Silicon Valley Bank
Pharming Group N.V. ("Pharming" or "the Company")( Euronext Amsterdam: PHARM) (Nasdaq: PHAR) is aware that the Federal Deposit Insurance Corporation ("FDIC") has been appointed receiver of Silicon Valley Bank ("SVB US") and that the Bank of England, barring any intervening events, intends to put Silicon Valley Bank UK Limited ("SVB UK") into insolvency.
PR Newswire
Notice of Full Year 2022 financial results
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce its unaudited Full Year 2022 financial results for the year ended December 31, 2022, on Thursday, March 16, 2023.